

PTI

Recombinant Bovine Aprotinin

Catalog No.	CRA135A	Quantity:	1.0 mg
	CRA135B		20 mg
	CRA135C		100 mg

Alternate Names: Pancreatic trypsin inhibitor, Basic protease inhibitor, BPI, BPTI, AP

Description: Recombinant Bovine Aprotinin is designed specifically for cell culture applications, protein purification, diagnostic testing and pharmaceuticals. It is produced in maize without the use of animal or human derived materials and is therefore free from the risk of contaminating human or animal derived viruses or prions.

Aprotinin inhibits the activity of several proteolytic enzymes such as chymotrypsin, kallikrein, plasmin and trypsin. Aprotinin is present in blood and in most tissues, with a high concentration in lung. Aprotinin inhibits pro-inflammatory cytokine release and maintains glycoprotein homeostasis. In platelets, aprotinin reduces glycoprotein loss (e.g., Gplb, GpIIb/IIIa), while in granulocytes it prevents the expression of pro-inflammatory adhesive glycoproteins (e.g., CD11b).

Gene ID: 404172

Protein Accession No: P00974

Source: Maize (corn)

Molecular Weight: 6.51 kDa

Formulation: Lyophilized from a sterile filtered solution without additives

Purity: > 90.0% as determined by gel electrophoresis

Endotoxin Level: < 0.1 ng/μg of Aprotinin

Biological Activity: 4.6 TIU/mg. One Trypsin inhibitory unit (TIU) is equal to the amount of the inhibitor with the ability to inhibit two trypsin units by 50% where one trypsin unit will hydrolyze 1.0 mmole of N-alpha-benzoyl-DL-Arginine-p-Nitroanilide (BAPNA) per minute at pH 7.8 at 25°C.

Reconstitution: **Centrifuge vial prior to opening.** First add sterile distilled water to the vial to fully solubilize the protein to a concentration not less than 100 μg/ml. After complete solubilization of the protein, it can be further diluted to other aqueous solutions.

Storage & Stability: Store lyophilized protein at 2-4°C.

NOT FOR HUMAN USE. FOR RESEARCH ONLY. NOT FOR DIAGNOSTIC OR THERAPEUTIC USE.